Suppressive effects of histamine skin reactivity by a nonsedating antihistamine-mequitazine.
The suppressive activity of mequitazine (MQZ) on histamine skin reactivity was evaluated in 29 healthy subjects (age 22-25 years) in a single-blind study. Fifteen subjects received MQZ, at a dosage of 5 mg BID, for 7 days while 14 served as controls. A prick skin test with saline or histamine hydrochloride (1 mg/ml and 10 mg/ml) was performed in duplicate, on both forearms, starting from the baseline day and continuing for 4 days after medication had been discontinued (total of 11 days). The skin-test subject and the reader was unaware of the randomization process. Mean diameters of wheal and flare as well as the skin index scores (after Voorhost) were used in the analysis. Maximal flare suppression (as compared to the baseline values) was observed on day 6 (97% suppression for 1 mg/ml and 54% suppression for 10 mg/ml, p less than 0.01). Suppression of wheal size was significant (19% for 1 mg/ml and 28% for 10 mg/ml) but was not clinically relevant. Suppression of skin index scores was maximal on day 6 (71% for 1 mg/ml and 43% for 10 mg/ml, p less than 0.01). After MQZ had been discontinued, all measurements gradually returned to baseline values and were not different therefrom within 3 days. However, final measurements of wheal and flare were smaller than baseline values (60-94% of baselines). We conclude that MQZ, at the manufacturers's recommended dose of 5 mg BID, significantly suppressed flare size of histamine skin tests and recommend that MQZ be discontinued for at least 3 days prior to performing allergy skin tests.
Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand.
P
P
Vichyanond
S
S
Jongpanichkultorn
N
N
Aranyanark
M
M
Tuchinda
D000328:Adult; D005260:Female; D006633:Histamine Antagonists; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D008297:Male; D010640:Phenothiazines / Q000008:administration & dosage / Q000494:pharmacology*; D016037:Single-Blind Method; D012867:Skin / Q000187:drug effects / Q000276:immunology*; D012882:Skin Tests
D006633:Histamine Antagonists; D006634:Histamine H1 Antagonists; D010640:Phenothiazines; C006069:mequitazine